Generic placeholder image

Current Pharmaceutical Biotechnology


ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Review Article

Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors

Author(s): Anna Campanati, Elisa Molinelli*, Valerio Brisigotti and Annamaria Offidani

Volume 18, Issue 12, 2017

Page: [945 - 963] Pages: 19

DOI: 10.2174/1389201019666180209121804

Price: $65


Background: Psoriasis is a chronic immune-mediated inflammatory disorder, with an estimated global prevalence of 2-3%. Psoriasis is associated with an impaired health-related quality of life and a substantial economic burden. Biologics, which target the pathways involved in the pathogenesis of psoriasis, represent an established therapeutic approach for moderate-to-severe plaque psoriasis, with remarkable efficacy and safety profile extensively examined and monitored.

Methods: Biological therapies currently available can be divided into three main categories: the TNFα antagonists (infliximab, adalimumab, etanercept, golimumab, certolizumab pegol), the interleukin (IL)- 12/23 monoclonal antibody (ustekinumab), and IL-17 inhibitor (secukinumab, ixekizumab).

Results: In this section, we explore the complex role of TNFα in psoriasis as well as the efficacy and safety of TNFα inhibitors largely used in the management of the cutaneous disease.

Conclusion: Dosing regimens, administration, pharmacodynamics profiles, efficacy, and safety of licensed anti-TNFα are here discussed in detail.

Keywords: Adalimumab, etanercept, golimumab, certolizumab pegol, infliximab, anti-TNFα, efficacy, safety.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy